Compounds > varespladib
Page last updated: 2024-09-04

varespladib and Disease Models, Animal

varespladib has been researched along with Disease Models, Animal in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV1
Gutiérrez, JM; Lewin, MR; Lomonte, B; Williams, DJ1
Antonelli, M; Capoluongo, ED; Conti, G; De Luca, D; Fraser, H; Gentile, L; Minucci, A; Perez-Gil, J; Trias, J; Vendittelli, F1
Behrendt, M; Dikkers, A; Gautier, T; Grass, DS; Hurt-Camejo, E; Rader, DJ; Rosengren, B; Tietge, UJ1
Bickler, P; Lewin, M; Merkel, J; Samuel, S1
Hori, Y; Koike, K; Ono, T; Yamamoto, Y1

Other Studies

6 other study(ies) available for varespladib and Disease Models, Animal

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection

2020
Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.
    Toxins, 2020, 02-20, Volume: 12, Issue:2

    Topics: Acetates; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Indoles; Keto Acids; Lethal Dose 50; Mice; Neurotoxicity Syndromes; Phospholipase A2 Inhibitors; Phospholipases A2; Snake Bites; Snake Venoms; Survival Analysis; Time Factors

2020
Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture.
    Current pharmaceutical biotechnology, 2013, Volume: 14, Issue:4

    Topics: Acetates; Acute Lung Injury; Animals; Cells, Cultured; Disease Models, Animal; Fatty Acids, Nonesterified; Indoles; Keto Acids; Macrophages, Alveolar; Phospholipases A2, Secretory; Pulmonary Surfactants; Rats; Tumor Necrosis Factor-alpha

2013
Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:12

    Topics: Acetates; Animals; Aorta; Aortic Diseases; Apolipoprotein E3; Apolipoproteins B; Atherosclerosis; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Group II Phospholipases A2; Humans; Hypercholesterolemia; Indoles; Keto Acids; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Plaque, Atherosclerotic

2013
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.
    Toxins, 2016, 08-25, Volume: 8, Issue:9

    Topics: Acetates; Animals; Antidotes; Disease Models, Animal; Dose-Response Relationship, Drug; Elapid Venoms; Indoles; Keto Acids; Mice; Phospholipase A2 Inhibitors; Phospholipases A2; Prodrugs; Rats, Sprague-Dawley; Reptilian Proteins; Snake Bites; Time Factors; Viper Venoms

2016
Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion.
    Annals of surgery, 2000, Volume: 232, Issue:1

    Topics: Acetates; Animals; Disease Models, Animal; Humans; Indoles; Intestines; Keto Acids; Liver; Lung; Male; Phospholipases A; Phospholipases A2; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Respiratory Distress Syndrome

2000